Kimberly Thompson
Psychiatric/Mental Health · Dallas, TXNPI 1649613035
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,500 of the $24,939 with a category attached, or 62.2%. AbbVie accounts for 68.6% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $17,960, 9.5 times the $1,885 reported in 2021. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $59.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- Alkermes, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$810
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$782
- Otsuka America Pharmaceutical, Inc.$613
- Corium, LLC$522
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$15,50062%
- Travel & lodging$2991%
- Food & beverage$9,09136%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 104 | $17,109 |
| Alkermes, Inc. | 41 | $1,064 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $810 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $782 |
| Otsuka America Pharmaceutical, Inc. | 27 | $613 |
| Corium, LLC | 18 | $522 |
| Axsome Therapeutics, Inc. | 15 | $497 |
| Neurocrine Biosciences, Inc. | 10 | $481 |
| Johnson & Johnson | 16 | $340 |
| Teva Pharmaceuticals USA, Inc. | 5 | $278 |
| Lundbeck LLC | 13 | $250 |
| Sunovion Pharmaceuticals Inc. | 15 | $240 |
| Vanda Pharmaceuticals Inc. | 10 | $234 |
| Tris Pharma Inc | 9 | $212 |
| Eisai Inc. | 6 | $187 |
| E.r. Squibb & Sons, L.L.C. | 4 | $177 |
| Bausch Health US, LLC | 8 | $155 |
| Almatica Pharma LLC | 7 | $155 |
| Ironshore Pharmaceuticals Inc. | 7 | $152 |
| Supernus Pharmaceuticals, Inc. | 8 | $139 |
| Noven Therapeutics, LLC | 7 | $132 |
| Validus Pharmaceuticals LLC | 3 | $131 |
| Alfasigma USA, Inc. | 4 | $82 |
| Merck | 3 | $56 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Orexo US, Inc. | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Noven Pharmaceuticals, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,939 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $81,252 |
| VraylarCariprazine Hcl | 12 | $16,670 |
| Fluphenazine Hcl | 22 | $3,165 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $801 |
| Ziprasidone Hcl | 13 | $683 |
| Trazodone Hcl | 54 | $560 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $432 |
| Clomipramine Hcl | 11 | $406 |
| Aripiprazole | 15 | $329 |
| Zolpidem Tartrate ErZolpidem Tartrate | 12 | $307 |
| Quetiapine Fumarate | 20 | $266 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $225 |
| Lamotrigine | 36 | $216 |
| Bupropion XlBupropion Hcl | 18 | $201 |
| Clonazepam | 27 | $166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $481 | $81,25211 claims |
| AbbVieVraylar | $17,109 | $16,67012 claims |
| Almatica Pharma LLCSertraline Hcl | $155 | $14520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Dallas
- Melissa RiveraDallas$19K
- Jillian AdamsDallas$13K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.